ReviewFrontiers in oncology2026
The CGRP-nociceptor axis in cancer: tumor-specific programs of immune evasion, stromal remodeling, and tumor growth.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer neuroscience has established that peripheral nerves can shape tumor growth and antitumor immunity, although the underlying mechanisms vary across malignancies. Calcitonin gene-related peptide (CGRP), released mainly by peptidergic nociceptors and sensed through the CALCRL/RAMP1 receptor complex, is emerging as a recurrent mediator of tumor-nerve communication. This review synthesizes current evidence for CGRP signaling across tumor types. In melanoma and head and neck squamous cell carcinoma (HNSCC), CGRP can directly suppress tumor-infiltrating T cell activity. In lung adenocarcinoma, it acts through a macrophage-fibroblast relay that limits tertiary lymphoid structure assembly. In medullary thyroid cancer, tumor-associated CGRP is linked to abnormal dendritic cell development. In pancreatic ductal adenocarcinoma, nociceptor-derived CGRP participates in a reciprocal interaction with cancer-associated fibroblasts that lowers IL-15 and suppresses natural killer cells. Additional studies identify tumor-intrinsic outputs, including gastric tumor growth, CGRP-dependent cytoprotective autophagy in oral cancer, and RAMP1-dependent growth in gastrointestinal cancer models. Liver data currently support a role in fibrogenesis, while the relevance of this pathway to hepatocellular carcinoma remains unresolved. Together, these findings support a shared nociceptor-CGRP signaling system with tumor-specific cellular outputs. CGRP-pathway drugs and nociceptor-directed interventions therefore warrant tumor-specific translational studies, although anticancer efficacy remains predominantly preclinical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.